I don’t agree with this . What if a company like Amgen bought efti, you’d see it deployed across all marketed checkpoint inhibitors. Any situation where tumor debris is created like ADC’s, bispecifics, or even targeted therapies for rare mutations like EGGR and KRAS. Through its ligand MHC-II efti is an APC activator increasing directed response to tumors.
it’s not Merck or bust, in fact Merck isn’t even in my top 5. Keytruda will certainly be a huge part of the efti franchise though.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.005(2.04%) |
Mkt cap ! $365.0M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.3¢ | 24.5¢ | $620.5K | 2.512M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 66277 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 22044 | 3 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| IMM (ASX) Chart |